Kepler Cheuvreux Suisse SA Raises Stake in Gilead Sciences, Inc. $GILD

Kepler Cheuvreux Suisse SA increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 57.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 130,328 shares of the biopharmaceutical company’s stock after buying an additional 47,719 shares during the period. Gilead Sciences comprises 1.2% of Kepler Cheuvreux Suisse SA’s portfolio, making the stock its 27th largest holding. Kepler Cheuvreux Suisse SA’s holdings in Gilead Sciences were worth $18,162,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC acquired a new position in Gilead Sciences in the fourth quarter valued at $26,000. Wealth Preservation Advisors LLC lifted its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on GILD shares. Truist Financial reissued a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Leerink Partners cut their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Daiwa Securities Group decreased their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $158.41.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $131.27 on Friday. The stock has a 50-day simple moving average of $129.44 and a 200-day simple moving average of $134.53. The stock has a market capitalization of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Activity

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 83,000 shares of company stock valued at $10,824,500. Company insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.